O
ENTA icon

OrbiMed’s Enanta Pharmaceuticals ENTA Stock Holding History

OrbiMed’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-233,100
Closed -$22.3M – 130
2019
Q1 		$22.3M Buy
+233,100
New +$20.9M 0.34% 68
2016
Q2 		– Sell
-249,400
Closed -$7.33M – 141
2016
Q1 		$7.33M Sell
249,400
-254,900
-51% -$7.1M 0.08% 103
2015
Q4 		$16.7M Buy
+504,300
New +$16.4M 0.15% 74

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed's ENTA Position: Q2 2019 in Review

OrbiMed sold out of Enanta Pharmaceuticals (ENTA) in Q2 2019, closing a stake of 233,100 shares — an estimated $22.3M sold.

OrbiMed first reported a position in ENTA in Q4 2015 and held it in 3 quarters. The position peaked at $22.3M in Q1 2019. 194 funds tracked by Wall St. Rank hold ENTA as of Q2 2019.

  • OrbiMed reported no remaining Enanta Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • OrbiMed sold 233,100 Enanta Pharmaceuticals shares in Q2 2019, an estimated $22.3M.
  • OrbiMed first reported a position in Enanta Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • OrbiMed's Enanta Pharmaceuticals position peaked at $22.3M in Q1 2019.
  • 194 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2019.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.